English

Oruka Therapeutics, Inc.

EDGAR

ABIO Current report (8-K) · filed 2026-10-26

193 filing records in this dataset, filed from 1997-09-12 to 2026-10-26. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

0 USD

2024-06-30 · USD

Exact inputs and evidence

Revenue: 0 USD Source
Revenue: 0 USD Source

Operating cash flow

-2.63 million USD

2024-06-30 · USD

Exact inputs and evidence

Operating Cash Flow: -4162000 USD Source
Operating Cash Flow: -1528000 USD Source

Cash and cash equivalents: 268 million USD 2026-06-30 Source
Exact value

268470000 USD
Long-term debt including current maturities: Not available
Shares outstanding: 61.1 million shares 2026-06-30 Source
Exact value

61069887 shares

Reported share-count change

63.07% · 23.6 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

37450745 shares · 2025-06-30· Source
61069887 shares · 2026-06-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

0 USD

2023-07-01 – 2024-06-30

Exact inputs and evidence

Revenue: 0 USD · 2023-01-01 – 2023-09-30 Source
Revenue: 0 USD · 2023-01-01 – 2023-06-30 Source
Revenue: 0 USD · 2023-01-01 – 2023-12-31 Source
Revenue: 0 USD · 2023-01-01 – 2023-09-30 Source
Revenue: 0 USD · 2024-01-01 – 2024-03-31 Source
Revenue: 0 USD · 2024-01-01 – 2024-06-30 Source
Revenue: 0 USD · 2024-01-01 – 2024-03-31 Source

Net income

-133 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Net income: -30277000 USD · 2025-07-01 – 2025-09-30 Source
Net income: -105433000 USD · 2025-01-01 – 2025-12-31 Source
Net income: -75850000 USD · 2025-01-01 – 2025-09-30 Source
Net income: -31820000 USD · 2026-01-01 – 2026-03-31 Source
Net income: -41206000 USD · 2026-04-01 – 2026-06-30 Source

Operating cash flow

-101 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -65600000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -44014000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -88210000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -65600000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -23578000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -56723000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -23578000 USD · 2026-01-01 – 2026-03-31 Source

Capital expenditure

235 thousand USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Capital expenditure: 146000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 47000 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 209000 USD · 2025-01-01 – 2025-12-31 Source
Capital expenditure: 146000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 73000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 73000 USD · 2026-01-01 – 2026-06-30 Source
Capital expenditure: 73000 USD · 2026-01-01 – 2026-03-31 Source

Free cash flow

-101 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -65600000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -44014000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -88210000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -65600000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -23578000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -56723000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -23578000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 146000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 47000 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 209000 USD · 2025-01-01 – 2025-12-31 Source
Capital expenditure: 146000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 73000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 73000 USD · 2026-01-01 – 2026-06-30 Source
Capital expenditure: 73000 USD · 2026-01-01 – 2026-03-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-10-26.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 9 of 11 periods available· newest 2023-12-31
Operating income: 10 of 11 periods available· newest 2025-12-31
Net income: 10 of 11 periods available· newest 2025-12-31
Operating cash flow: 10 of 11 periods available· newest 2025-12-31
Capital expenditure: 10 of 11 periods available· newest 2025-12-31
Total assets: 10 of 11 periods available· newest 2025-12-31
Total liabilities: 10 of 11 periods available· newest 2025-12-31
Current assets: 10 of 11 periods available· newest 2025-12-31
Current liabilities: 10 of 11 periods available· newest 2025-12-31
Cash and cash equivalents: 10 of 11 periods available· newest 2025-12-31
long term debt: No compatible figures in this window
Shares outstanding: 10 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

No unambiguous prior-year comparison is available for the latest reporting period.

Comparable inputs unavailable for: Revenue, Net income, Operating cash flow, Capital expenditure.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2023 2023-01-01 – 2023-12-31

Revenue USD 0
Operating costs Derived USD 7.3 million
Operating income −USD 7.3 million
Tax, interest and other Derived −USD 1.96 million
Net income −USD 5.34 million

Cash

Operating cash flow −USD 5.01 million
Capital expenditure USD 0
Free cash flow Derived −USD 5.01 million

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2015 Not shown: operating income or net income is not reported.
2016 Not shown: operating income or net income is not reported.
2017 Not shown: operating income or net income is not reported.
2018 Not shown: operating income or net income is not reported.
2019 Not shown: operating income or net income is not reported.
2020 Not shown: operating income or net income is not reported.
2021 Not shown: operating income or net income is not reported.
2022 Not shown: operating income or net income is not reported.
2023 Not shown: operating income or net income is not reported.

Values and sources

Revenue breakdown by annual reporting period
Period	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2015 2015-01-01 – 2015-12-31	11455000 Derived	-11455000	-10000 Derived	-11445000	-10545000 Derived	Source 2015-01-01 – 2015-12-31: 0 USD Inspect Revenue Open source 2015-01-01 – 2015-12-31: -11455000 USD Inspect Operating Income Open source 2015-01-01 – 2015-12-31: -11445000 USD Inspect Net Income Open source 2015-01-01 – 2015-12-31: -10534000 USD Inspect Operating Cash Flow Open source 2015-01-01 – 2015-12-31: 11000 USD Inspect Capital Expenditure Open source
2016 2016-01-01 – 2016-12-31	16613000 Derived	-16613000	-169000 Derived	-16444000	-14999000 Derived	Source 2016-01-01 – 2016-12-31: 0 USD Inspect Revenue Open source 2016-01-01 – 2016-12-31: -16613000 USD Inspect Operating Income Open source 2016-01-01 – 2016-12-31: -16444000 USD Inspect Net Income Open source 2016-01-01 – 2016-12-31: -14987000 USD Inspect Operating Cash Flow Open source 2016-01-01 – 2016-12-31: 12000 USD Inspect Capital Expenditure Open source
2017 2017-01-01 – 2017-12-31	18712000 Derived	-18712000	-222000 Derived	-18490000	-17475000 Derived	Source 2017-01-01 – 2017-12-31: 0 USD Inspect Revenue Open source 2017-01-01 – 2017-12-31: -18712000 USD Inspect Operating Income Open source 2017-01-01 – 2017-12-31: -18490000 USD Inspect Net Income Open source 2017-01-01 – 2017-12-31: -17472000 USD Inspect Operating Cash Flow Open source 2017-01-01 – 2017-12-31: 3000 USD Inspect Capital Expenditure Open source
2018 2018-01-01 – 2018-12-31	8118000 Derived	-8118000	-185000 Derived	-7933000	-8248000 Derived	Source 2018-01-01 – 2018-12-31: 0 USD Inspect Revenue Open source 2018-01-01 – 2018-12-31: -8118000 USD Inspect Operating Income Open source 2018-01-01 – 2018-12-31: -7933000 USD Inspect Net Income Open source 2018-01-01 – 2018-12-31: -8244000 USD Inspect Operating Cash Flow Open source 2018-01-01 – 2018-12-31: 4000 USD Inspect Capital Expenditure Open source
2019 2019-01-01 – 2019-12-31	5814000 Derived	-5814000	-332000 Derived	-5482000	-4805000 Derived	Source 2019-01-01 – 2019-12-31: 0 USD Inspect Revenue Open source 2019-01-01 – 2019-12-31: -5814000 USD Inspect Operating Income Open source 2019-01-01 – 2019-12-31: -5482000 USD Inspect Net Income Open source 2019-01-01 – 2019-12-31: -4801000 USD Inspect Operating Cash Flow Open source 2019-01-01 – 2019-12-31: 4000 USD Inspect Capital Expenditure Open source
2020 2020-01-01 – 2020-12-31	9766000 Derived	-9766000	-28000 Derived	-9738000	-7744000 Derived	Source 2020-01-01 – 2020-12-31: 0 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -9766000 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -9738000 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: -7725000 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 19000 USD Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	19335000 Derived	-19335000	-13000 Derived	-19322000	-18805000 Derived	Source 2021-01-01 – 2021-12-31: 0 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -19335000 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -19322000 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: -18762000 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 43000 USD Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	10596000 Derived	-10596000	-670000 Derived	-9926000	-10914000 Derived	Source 2022-01-01 – 2022-12-31: 0 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -10596000 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -9926000 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: -10912000 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 2000 USD Inspect Capital Expenditure Open source
2023 2023-01-01 – 2023-12-31	7296000 Derived	-7296000	-1957000 Derived	-5339000	-5014000 Derived	Source 2023-01-01 – 2023-12-31: 0 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: -7296000 USD Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -5339000 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: -5014000 USD Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 0 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 0 2023

Values and sources

Revenue values and source evidence
Period	Series	Source evidence
20152015-12-31	Revenue	Revenue: 0 Open source
20162016-12-31	Revenue	Revenue: 0 Open source
20172017-12-31	Revenue	Revenue: 0 Open source
20182018-12-31	Revenue	Revenue: 0 Open source
20192019-12-31	Revenue	Revenue: 0 Open source
20202020-12-31	Revenue	Revenue: 0 Open source
20212021-12-31	Revenue	Revenue: 0 Open source
20222022-12-31	Revenue	Revenue: 0 Open source
20232023-12-31	Revenue	Revenue: 0 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

Not enough comparable data to show this history.

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20152015-12-31	Year over year	No prior comparable period	Revenue: 0 Open source
20162016-12-31	Year over year	No prior comparable period	Revenue: 0 Open source Revenue: 0 Open source
20172017-12-31	Year over year	No prior comparable period	Revenue: 0 Open source Revenue: 0 Open source
20182018-12-31	Year over year	No prior comparable period	Revenue: 0 Open source Revenue: 0 Open source
20192019-12-31	Year over year	No prior comparable period	Revenue: 0 Open source Revenue: 0 Open source
20202020-12-31	Year over year	No prior comparable period	Revenue: 0 Open source Revenue: 0 Open source
20212021-12-31	Year over year	No prior comparable period	Revenue: 0 Open source Revenue: 0 Open source
20222022-12-31	Year over year	No prior comparable period	Revenue: 0 Open source Revenue: 0 Open source
20232023-12-31	Year over year	No prior comparable period	Revenue: 0 Open source Revenue: 0 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Not enough comparable data to show this history.

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20152015-12-31	Operating margin	Not reported	Operating Income: -11455000 Open source Revenue: 0 Open source
20162016-12-31	Operating margin	Not reported	Operating Income: -16613000 Open source Revenue: 0 Open source
20172017-12-31	Operating margin	Not reported	Operating Income: -18712000 Open source Revenue: 0 Open source
20182018-12-31	Operating margin	Not reported	Operating Income: -8118000 Open source Revenue: 0 Open source
20192019-12-31	Operating margin	Not reported	Operating Income: -5814000 Open source Revenue: 0 Open source
20202020-12-31	Operating margin	Not reported	Operating Income: -9766000 Open source Revenue: 0 Open source
20212021-12-31	Operating margin	Not reported	Operating Income: -19335000 Open source Revenue: 0 Open source
20222022-12-31	Operating margin	Not reported	Operating Income: -10596000 Open source Revenue: 0 Open source
20232023-12-31	Operating margin	Not reported	Operating Income: -7296000 Open source Revenue: 0 Open source
20152015-12-31	Net margin	Not reported	Net Income: -11445000 Open source Revenue: 0 Open source
20162016-12-31	Net margin	Not reported	Net Income: -16444000 Open source Revenue: 0 Open source
20172017-12-31	Net margin	Not reported	Net Income: -18490000 Open source Revenue: 0 Open source
20182018-12-31	Net margin	Not reported	Net Income: -7933000 Open source Revenue: 0 Open source
20192019-12-31	Net margin	Not reported	Net Income: -5482000 Open source Revenue: 0 Open source
20202020-12-31	Net margin	Not reported	Net Income: -9738000 Open source Revenue: 0 Open source
20212021-12-31	Net margin	Not reported	Net Income: -19322000 Open source Revenue: 0 Open source
20222022-12-31	Net margin	Not reported	Net Income: -9926000 Open source Revenue: 0 Open source
20232023-12-31	Net margin	Not reported	Net Income: -5339000 Open source Revenue: 0 Open source
20152015-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -10534000 Open source Capital Expenditure: 11000 Open source
20162016-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -14987000 Open source Capital Expenditure: 12000 Open source
20172017-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -17472000 Open source Capital Expenditure: 3000 Open source
20182018-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -8244000 Open source Capital Expenditure: 4000 Open source
20192019-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -4801000 Open source Capital Expenditure: 4000 Open source
20202020-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -7725000 Open source Capital Expenditure: 19000 Open source
20212021-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -18762000 Open source Capital Expenditure: 43000 Open source
20222022-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -10912000 Open source Capital Expenditure: 2000 Open source
20232023-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -5014000 Open source Capital Expenditure: 0 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -5M 2023

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20152015-12-31	Operating cash flow	-10534000	Operating Cash Flow: -10534000 Open source
20162016-12-31	Operating cash flow	-14987000	Operating Cash Flow: -14987000 Open source
20172017-12-31	Operating cash flow	-17472000	Operating Cash Flow: -17472000 Open source
20182018-12-31	Operating cash flow	-8244000	Operating Cash Flow: -8244000 Open source
20192019-12-31	Operating cash flow	-4801000	Operating Cash Flow: -4801000 Open source
20202020-12-31	Operating cash flow	-7725000	Operating Cash Flow: -7725000 Open source
20212021-12-31	Operating cash flow	-18762000	Operating Cash Flow: -18762000 Open source
20222022-12-31	Operating cash flow	-10912000	Operating Cash Flow: -10912000 Open source
20232023-12-31	Operating cash flow	-5014000	Operating Cash Flow: -5014000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -5M 2023

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20152015-12-31	Free cash flow	-10545000	Operating Cash Flow: -10534000 Open source Capital Expenditure: 11000 Open source
20162016-12-31	Free cash flow	-14999000	Operating Cash Flow: -14987000 Open source Capital Expenditure: 12000 Open source
20172017-12-31	Free cash flow	-17475000	Operating Cash Flow: -17472000 Open source Capital Expenditure: 3000 Open source
20182018-12-31	Free cash flow	-8248000	Operating Cash Flow: -8244000 Open source Capital Expenditure: 4000 Open source
20192019-12-31	Free cash flow	-4805000	Operating Cash Flow: -4801000 Open source Capital Expenditure: 4000 Open source
20202020-12-31	Free cash flow	-7744000	Operating Cash Flow: -7725000 Open source Capital Expenditure: 19000 Open source
20212021-12-31	Free cash flow	-18805000	Operating Cash Flow: -18762000 Open source Capital Expenditure: 43000 Open source
20222022-12-31	Free cash flow	-10914000	Operating Cash Flow: -10912000 Open source Capital Expenditure: 2000 Open source
20232023-12-31	Free cash flow	-5014000	Operating Cash Flow: -5014000 Open source Capital Expenditure: 0 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

2.2% 2023

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20152015-12-31	Liabilities / assets	3.8%	Total Liabilities: 1504000 Open source Total Assets: 39574000 Open source
20162016-12-31	Liabilities / assets	9.9%	Total Liabilities: 2435000 Open source Total Assets: 24629000 Open source
20172017-12-31	Liabilities / assets	16.9%	Total Liabilities: 2090000 Open source Total Assets: 12365000 Open source
20182018-12-31	Liabilities / assets	11.6%	Total Liabilities: 793000 Open source Total Assets: 6825000 Open source
20192019-12-31	Liabilities / assets	10.8%	Total Liabilities: 926000 Open source Total Assets: 8536000 Open source
20202020-12-31	Liabilities / assets	7.7%	Total Liabilities: 3908000 Open source Total Assets: 50429000 Open source
20212021-12-31	Liabilities / assets	7.1%	Total Liabilities: 3881000 Open source Total Assets: 54924000 Open source
20222022-12-31	Liabilities / assets	3.3%	Total Liabilities: 1412000 Open source Total Assets: 43085000 Open source
20232023-12-31	Liabilities / assets	2.2%	Total Liabilities: 841000 Open source Total Assets: 37861000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

59.01× 2023

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20152015-12-31	Current assets / current liabilities	25.88×	Current Assets: 38916000 Open source Current Liabilities: 1504000 Open source
20162016-12-31	Current assets / current liabilities	8.95×	Current Assets: 21445000 Open source Current Liabilities: 2396000 Open source
20172017-12-31	Current assets / current liabilities	5.94×	Current Assets: 12299000 Open source Current Liabilities: 2070000 Open source
20182018-12-31	Current assets / current liabilities	8.55×	Current Assets: 6777000 Open source Current Liabilities: 793000 Open source
20192019-12-31	Current assets / current liabilities	9.16×	Current Assets: 8480000 Open source Current Liabilities: 926000 Open source
20202020-12-31	Current assets / current liabilities	14.28×	Current Assets: 49968000 Open source Current Liabilities: 3499000 Open source
20212021-12-31	Current assets / current liabilities	15.56×	Current Assets: 54421000 Open source Current Liabilities: 3498000 Open source
20222022-12-31	Current assets / current liabilities	37.72×	Current Assets: 42699000 Open source Current Liabilities: 1132000 Open source
20232023-12-31	Current assets / current liabilities	59.01×	Current Assets: 37592000 Open source Current Liabilities: 637000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2015 2015-01-01 – 2015-12-31	−USD 11.45 million Exact value Exact value: -11445000 USD 2015-01-01 – 2015-12-31: -11445000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Oruka Therapeutics, Inc. · 2015-12-31 Oruka Therapeutics, Inc. (edgar:907654) Net Income: -11445000 USD Concept: fundies:NetIncome Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T15:40:21Z Snapshot: bf025b1e1791244d1c34a3c2856ab5b9c5c3550eb14e95c1b413f80a21684075 Dimensions: Consolidated View: https://fundies.io/companies/edgar/907654/explain?concept=fundies%3ANetIncome&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:NetIncome: -11445000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/907654/000156459017004897/abio-20161231.xml#77464 Filing: 000156459017004897 The citation records this snapshot. The page link may show a newer release later.	−USD 10.53 million Exact value Exact value: -10534000 USD 2015-01-01 – 2015-12-31: -10534000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Oruka Therapeutics, Inc. · 2015-12-31 Oruka Therapeutics, Inc. (edgar:907654) Operating Cash Flow: -10534000 USD Concept: fundies:OperatingCashFlow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T15:40:21Z Snapshot: bf025b1e1791244d1c34a3c2856ab5b9c5c3550eb14e95c1b413f80a21684075 Dimensions: Consolidated View: https://fundies.io/companies/edgar/907654/explain?concept=fundies%3AOperatingCashFlow&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -10534000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/907654/000156459017004897/abio-20161231.xml#93990 Filing: 000156459017004897 The citation records this snapshot. The page link may show a newer release later.	USD 11,000 Exact value Exact value: 11000 USD 2015-01-01 – 2015-12-31: 11000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Oruka Therapeutics, Inc. · 2015-12-31 Oruka Therapeutics, Inc. (edgar:907654) Capital Expenditure: 11000 USD Concept: fundies:CapitalExpenditure Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T15:40:21Z Snapshot: bf025b1e1791244d1c34a3c2856ab5b9c5c3550eb14e95c1b413f80a21684075 Dimensions: Consolidated View: https://fundies.io/companies/edgar/907654/explain?concept=fundies%3ACapitalExpenditure&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 11000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/907654/000156459017004897/abio-20161231.xml#94450 Filing: 000156459017004897 The citation records this snapshot. The page link may show a newer release later.	−USD 10.55 million Calculation and evidence -10534000 − 11000 USD Exact free cash flow: -10545000 USD 2015-01-01 – 2015-12-31: -10534000 USD · Inspect Operating Cash Flow · Source 2015-01-01 – 2015-12-31: 11000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Oruka Therapeutics, Inc. · 2015-12-31 Oruka Therapeutics, Inc. (edgar:907654) Free cash flow: -10545000 USD Concept: free-cash-flow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T15:40:21Z Snapshot: bf025b1e1791244d1c34a3c2856ab5b9c5c3550eb14e95c1b413f80a21684075 Dimensions: Consolidated View: https://fundies.io/companies/edgar/907654?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -10534000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/907654/000156459017004897/abio-20161231.xml#93990 Filing: 000156459017004897 Input fundies:CapitalExpenditure: 11000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/907654/000156459017004897/abio-20161231.xml#94450 Filing: 000156459017004897 The citation records this snapshot. The page link may show a newer release later.
2016 2016-01-01 – 2016-12-31	−USD 16.44 million Exact value Exact value: -16444000 USD 2016-01-01 – 2016-12-31: -16444000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Oruka Therapeutics, Inc. · 2016-12-31 Oruka Therapeutics, Inc. (edgar:907654) Net Income: -16444000 USD Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T15:40:21Z Snapshot: bf025b1e1791244d1c34a3c2856ab5b9c5c3550eb14e95c1b413f80a21684075 Dimensions: Consolidated View: https://fundies.io/companies/edgar/907654/explain?concept=fundies%3ANetIncome&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:NetIncome: -16444000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/907654/000156459018006566/abio-20171231.xml#80029 Filing: 000156459018006566 The citation records this snapshot. The page link may show a newer release later.	−USD 14.99 million Exact value Exact value: -14987000 USD 2016-01-01 – 2016-12-31: -14987000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Oruka Therapeutics, Inc. · 2016-12-31 Oruka Therapeutics, Inc. (edgar:907654) Operating Cash Flow: -14987000 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T15:40:21Z Snapshot: bf025b1e1791244d1c34a3c2856ab5b9c5c3550eb14e95c1b413f80a21684075 Dimensions: Consolidated View: https://fundies.io/companies/edgar/907654/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -14987000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/907654/000156459018006566/abio-20171231.xml#97053 Filing: 000156459018006566 The citation records this snapshot. The page link may show a newer release later.	USD 12,000 Exact value Exact value: 12000 USD 2016-01-01 – 2016-12-31: 12000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Oruka Therapeutics, Inc. · 2016-12-31 Oruka Therapeutics, Inc. (edgar:907654) Capital Expenditure: 12000 USD Concept: fundies:CapitalExpenditure Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T15:40:21Z Snapshot: bf025b1e1791244d1c34a3c2856ab5b9c5c3550eb14e95c1b413f80a21684075 Dimensions: Consolidated View: https://fundies.io/companies/edgar/907654/explain?concept=fundies%3ACapitalExpenditure&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 12000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/907654/000156459018006566/abio-20171231.xml#97512 Filing: 000156459018006566 The citation records this snapshot. The page link may show a newer release later.	−USD 15 million Calculation and evidence -14987000 − 12000 USD Exact free cash flow: -14999000 USD 2016-01-01 – 2016-12-31: -14987000 USD · Inspect Operating Cash Flow · Source 2016-01-01 – 2016-12-31: 12000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Oruka Therapeutics, Inc. · 2016-12-31 Oruka Therapeutics, Inc. (edgar:907654) Free cash flow: -14999000 USD Concept: free-cash-flow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T15:40:21Z Snapshot: bf025b1e1791244d1c34a3c2856ab5b9c5c3550eb14e95c1b413f80a21684075 Dimensions: Consolidated View: https://fundies.io/companies/edgar/907654?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -14987000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/907654/000156459018006566/abio-20171231.xml#97053 Filing: 000156459018006566 Input fundies:CapitalExpenditure: 12000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/907654/000156459018006566/abio-20171231.xml#97512 Filing: 000156459018006566 The citation records this snapshot. The page link may show a newer release later.
2017 2017-01-01 – 2017-12-31	−USD 18.49 million Exact value Exact value: -18490000 USD 2017-01-01 – 2017-12-31: -18490000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Oruka Therapeutics, Inc. · 2017-12-31 Oruka Therapeutics, Inc. (edgar:907654) Net Income: -18490000 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T15:40:21Z Snapshot: bf025b1e1791244d1c34a3c2856ab5b9c5c3550eb14e95c1b413f80a21684075 Dimensions: Consolidated View: https://fundies.io/companies/edgar/907654/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: -18490000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/907654/000156459019004882/abio-20181231.xml#78395 Filing: 000156459019004882 The citation records this snapshot. The page link may show a newer release later.	−USD 17.47 million Exact value Exact value: -17472000 USD 2017-01-01 – 2017-12-31: -17472000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Oruka Therapeutics, Inc. · 2017-12-31 Oruka Therapeutics, Inc. (edgar:907654) Operating Cash Flow: -17472000 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T15:40:21Z Snapshot: bf025b1e1791244d1c34a3c2856ab5b9c5c3550eb14e95c1b413f80a21684075 Dimensions: Consolidated View: https://fundies.io/companies/edgar/907654/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -17472000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/907654/000156459019004882/abio-20181231.xml#95299 Filing: 000156459019004882 The citation records this snapshot. The page link may show a newer release later.	USD 3,000 Exact value Exact value: 3000 USD 2017-01-01 – 2017-12-31: 3000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Oruka Therapeutics, Inc. · 2017-12-31 Oruka Therapeutics, Inc. (edgar:907654) Capital Expenditure: 3000 USD Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T15:40:21Z Snapshot: bf025b1e1791244d1c34a3c2856ab5b9c5c3550eb14e95c1b413f80a21684075 Dimensions: Consolidated View: https://fundies.io/companies/edgar/907654/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 3000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/907654/000156459019004882/abio-20181231.xml#95718 Filing: 000156459019004882 The citation records this snapshot. The page link may show a newer release later.	−USD 17.48 million Calculation and evidence -17472000 − 3000 USD Exact free cash flow: -17475000 USD 2017-01-01 – 2017-12-31: -17472000 USD · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 3000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Oruka Therapeutics, Inc. · 2017-12-31 Oruka Therapeutics, Inc. (edgar:907654) Free cash flow: -17475000 USD Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T15:40:21Z Snapshot: bf025b1e1791244d1c34a3c2856ab5b9c5c3550eb14e95c1b413f80a21684075 Dimensions: Consolidated View: https://fundies.io/companies/edgar/907654?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -17472000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/907654/000156459019004882/abio-20181231.xml#95299 Filing: 000156459019004882 Input fundies:CapitalExpenditure: 3000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/907654/000156459019004882/abio-20181231.xml#95718 Filing: 000156459019004882 The citation records this snapshot. The page link may show a newer release later.
2018 2018-01-01 – 2018-12-31	−USD 7.93 million Exact value Exact value: -7933000 USD 2018-01-01 – 2018-12-31: -7933000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Oruka Therapeutics, Inc. · 2018-12-31 Oruka Therapeutics, Inc. (edgar:907654) Net Income: -7933000 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T15:40:21Z Snapshot: bf025b1e1791244d1c34a3c2856ab5b9c5c3550eb14e95c1b413f80a21684075 Dimensions: Consolidated View: https://fundies.io/companies/edgar/907654/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -7933000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/907654/000156459020005032/abio-20191231.xml#71259 Filing: 000156459020005032 The citation records this snapshot. The page link may show a newer release later.	−USD 8.24 million Exact value Exact value: -8244000 USD 2018-01-01 – 2018-12-31: -8244000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Oruka Therapeutics, Inc. · 2018-12-31 Oruka Therapeutics, Inc. (edgar:907654) Operating Cash Flow: -8244000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T15:40:21Z Snapshot: bf025b1e1791244d1c34a3c2856ab5b9c5c3550eb14e95c1b413f80a21684075 Dimensions: Consolidated View: https://fundies.io/companies/edgar/907654/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -8244000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/907654/000156459020005032/abio-20191231.xml#85209 Filing: 000156459020005032 The citation records this snapshot. The page link may show a newer release later.	USD 4,000 Exact value Exact value: 4000 USD 2018-01-01 – 2018-12-31: 4000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Oruka Therapeutics, Inc. · 2018-12-31 Oruka Therapeutics, Inc. (edgar:907654) Capital Expenditure: 4000 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T15:40:21Z Snapshot: bf025b1e1791244d1c34a3c2856ab5b9c5c3550eb14e95c1b413f80a21684075 Dimensions: Consolidated View: https://fundies.io/companies/edgar/907654/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 4000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/907654/000156459020005032/abio-20191231.xml#85627 Filing: 000156459020005032 The citation records this snapshot. The page link may show a newer release later.	−USD 8.25 million Calculation and evidence -8244000 − 4000 USD Exact free cash flow: -8248000 USD 2018-01-01 – 2018-12-31: -8244000 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 4000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Oruka Therapeutics, Inc. · 2018-12-31 Oruka Therapeutics, Inc. (edgar:907654) Free cash flow: -8248000 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T15:40:21Z Snapshot: bf025b1e1791244d1c34a3c2856ab5b9c5c3550eb14e95c1b413f80a21684075 Dimensions: Consolidated View: https://fundies.io/companies/edgar/907654?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -8244000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/907654/000156459020005032/abio-20191231.xml#85209 Filing: 000156459020005032 Input fundies:CapitalExpenditure: 4000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/907654/000156459020005032/abio-20191231.xml#85627 Filing: 000156459020005032 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	−USD 5.48 million Exact value Exact value: -5482000 USD 2019-01-01 – 2019-12-31: -5482000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Oruka Therapeutics, Inc. · 2019-12-31 Oruka Therapeutics, Inc. (edgar:907654) Net Income: -5482000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T15:40:21Z Snapshot: bf025b1e1791244d1c34a3c2856ab5b9c5c3550eb14e95c1b413f80a21684075 Dimensions: Consolidated View: https://fundies.io/companies/edgar/907654/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -5482000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/907654/000156459021014148/abio-20201231.xml#67453 Filing: 000156459021014148 The citation records this snapshot. The page link may show a newer release later.	−USD 4.8 million Exact value Exact value: -4801000 USD 2019-01-01 – 2019-12-31: -4801000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Oruka Therapeutics, Inc. · 2019-12-31 Oruka Therapeutics, Inc. (edgar:907654) Operating Cash Flow: -4801000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T15:40:21Z Snapshot: bf025b1e1791244d1c34a3c2856ab5b9c5c3550eb14e95c1b413f80a21684075 Dimensions: Consolidated View: https://fundies.io/companies/edgar/907654/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -4801000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/907654/000156459021014148/abio-20201231.xml#78811 Filing: 000156459021014148 The citation records this snapshot. The page link may show a newer release later.	USD 4,000 Exact value Exact value: 4000 USD 2019-01-01 – 2019-12-31: 4000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Oruka Therapeutics, Inc. · 2019-12-31 Oruka Therapeutics, Inc. (edgar:907654) Capital Expenditure: 4000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T15:40:21Z Snapshot: bf025b1e1791244d1c34a3c2856ab5b9c5c3550eb14e95c1b413f80a21684075 Dimensions: Consolidated View: https://fundies.io/companies/edgar/907654/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 4000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/907654/000156459021014148/abio-20201231.xml#79230 Filing: 000156459021014148 The citation records this snapshot. The page link may show a newer release later.	−USD 4.81 million Calculation and evidence -4801000 − 4000 USD Exact free cash flow: -4805000 USD 2019-01-01 – 2019-12-31: -4801000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 4000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Oruka Therapeutics, Inc. · 2019-12-31 Oruka Therapeutics, Inc. (edgar:907654) Free cash flow: -4805000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T15:40:21Z Snapshot: bf025b1e1791244d1c34a3c2856ab5b9c5c3550eb14e95c1b413f80a21684075 Dimensions: Consolidated View: https://fundies.io/companies/edgar/907654?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -4801000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/907654/000156459021014148/abio-20201231.xml#78811 Filing: 000156459021014148 Input fundies:CapitalExpenditure: 4000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/907654/000156459021014148/abio-20201231.xml#79230 Filing: 000156459021014148 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 9.74 million Exact value Exact value: -9738000 USD 2020-01-01 – 2020-12-31: -9738000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Oruka Therapeutics, Inc. · 2020-12-31 Oruka Therapeutics, Inc. (edgar:907654) Net Income: -9738000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T15:40:21Z Snapshot: bf025b1e1791244d1c34a3c2856ab5b9c5c3550eb14e95c1b413f80a21684075 Dimensions: Consolidated View: https://fundies.io/companies/edgar/907654/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -9738000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/907654/000156459022010075/abio-10k_20211231.htm#1137838 Filing: 000156459022010075 The citation records this snapshot. The page link may show a newer release later.	−USD 7.73 million Exact value Exact value: -7725000 USD 2020-01-01 – 2020-12-31: -7725000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Oruka Therapeutics, Inc. · 2020-12-31 Oruka Therapeutics, Inc. (edgar:907654) Operating Cash Flow: -7725000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T15:40:21Z Snapshot: bf025b1e1791244d1c34a3c2856ab5b9c5c3550eb14e95c1b413f80a21684075 Dimensions: Consolidated View: https://fundies.io/companies/edgar/907654/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -7725000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/907654/000156459022010075/abio-10k_20211231.htm#1176930 Filing: 000156459022010075 The citation records this snapshot. The page link may show a newer release later.	USD 19,000 Exact value Exact value: 19000 USD 2020-01-01 – 2020-12-31: 19000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Oruka Therapeutics, Inc. · 2020-12-31 Oruka Therapeutics, Inc. (edgar:907654) Capital Expenditure: 19000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T15:40:21Z Snapshot: bf025b1e1791244d1c34a3c2856ab5b9c5c3550eb14e95c1b413f80a21684075 Dimensions: Consolidated View: https://fundies.io/companies/edgar/907654/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 19000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/907654/000156459022010075/abio-10k_20211231.htm#1183826 Filing: 000156459022010075 The citation records this snapshot. The page link may show a newer release later.	−USD 7.74 million Calculation and evidence -7725000 − 19000 USD Exact free cash flow: -7744000 USD 2020-01-01 – 2020-12-31: -7725000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 19000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Oruka Therapeutics, Inc. · 2020-12-31 Oruka Therapeutics, Inc. (edgar:907654) Free cash flow: -7744000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T15:40:21Z Snapshot: bf025b1e1791244d1c34a3c2856ab5b9c5c3550eb14e95c1b413f80a21684075 Dimensions: Consolidated View: https://fundies.io/companies/edgar/907654?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -7725000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/907654/000156459022010075/abio-10k_20211231.htm#1176930 Filing: 000156459022010075 Input fundies:CapitalExpenditure: 19000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/907654/000156459022010075/abio-10k_20211231.htm#1183826 Filing: 000156459022010075 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 19.32 million Exact value Exact value: -19322000 USD 2021-01-01 – 2021-12-31: -19322000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Oruka Therapeutics, Inc. · 2021-12-31 Oruka Therapeutics, Inc. (edgar:907654) Net Income: -19322000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T15:40:21Z Snapshot: bf025b1e1791244d1c34a3c2856ab5b9c5c3550eb14e95c1b413f80a21684075 Dimensions: Consolidated View: https://fundies.io/companies/edgar/907654/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -19322000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/907654/000095017023004379/abio-20221231.htm#1216579 Filing: 000095017023004379 The citation records this snapshot. The page link may show a newer release later.	−USD 18.76 million Exact value Exact value: -18762000 USD 2021-01-01 – 2021-12-31: -18762000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Oruka Therapeutics, Inc. · 2021-12-31 Oruka Therapeutics, Inc. (edgar:907654) Operating Cash Flow: -18762000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T15:40:21Z Snapshot: bf025b1e1791244d1c34a3c2856ab5b9c5c3550eb14e95c1b413f80a21684075 Dimensions: Consolidated View: https://fundies.io/companies/edgar/907654/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -18762000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/907654/000095017023004379/abio-20221231.htm#1264065 Filing: 000095017023004379 The citation records this snapshot. The page link may show a newer release later.	USD 43,000 Exact value Exact value: 43000 USD 2021-01-01 – 2021-12-31: 43000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Oruka Therapeutics, Inc. · 2021-12-31 Oruka Therapeutics, Inc. (edgar:907654) Capital Expenditure: 43000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T15:40:21Z Snapshot: bf025b1e1791244d1c34a3c2856ab5b9c5c3550eb14e95c1b413f80a21684075 Dimensions: Consolidated View: https://fundies.io/companies/edgar/907654/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 43000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/907654/000095017023004379/abio-20221231.htm#1271273 Filing: 000095017023004379 The citation records this snapshot. The page link may show a newer release later.	−USD 18.81 million Calculation and evidence -18762000 − 43000 USD Exact free cash flow: -18805000 USD 2021-01-01 – 2021-12-31: -18762000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 43000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Oruka Therapeutics, Inc. · 2021-12-31 Oruka Therapeutics, Inc. (edgar:907654) Free cash flow: -18805000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T15:40:21Z Snapshot: bf025b1e1791244d1c34a3c2856ab5b9c5c3550eb14e95c1b413f80a21684075 Dimensions: Consolidated View: https://fundies.io/companies/edgar/907654?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -18762000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/907654/000095017023004379/abio-20221231.htm#1264065 Filing: 000095017023004379 Input fundies:CapitalExpenditure: 43000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/907654/000095017023004379/abio-20221231.htm#1271273 Filing: 000095017023004379 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 9.93 million Exact value Exact value: -9926000 USD 2022-01-01 – 2022-12-31: -9926000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Oruka Therapeutics, Inc. · 2022-12-31 Oruka Therapeutics, Inc. (edgar:907654) Net Income: -9926000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T15:40:21Z Snapshot: bf025b1e1791244d1c34a3c2856ab5b9c5c3550eb14e95c1b413f80a21684075 Dimensions: Consolidated View: https://fundies.io/companies/edgar/907654/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -9926000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea0205122-01.htm#6277691 Filing: 000121390024042529 The citation records this snapshot. The page link may show a newer release later.	−USD 10.91 million Exact value Exact value: -10912000 USD 2022-01-01 – 2022-12-31: -10912000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Oruka Therapeutics, Inc. · 2022-12-31 Oruka Therapeutics, Inc. (edgar:907654) Operating Cash Flow: -10912000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T15:40:21Z Snapshot: bf025b1e1791244d1c34a3c2856ab5b9c5c3550eb14e95c1b413f80a21684075 Dimensions: Consolidated View: https://fundies.io/companies/edgar/907654/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -10912000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea0205122-01.htm#6352025 Filing: 000121390024042529 The citation records this snapshot. The page link may show a newer release later.	USD 2,000 Exact value Exact value: 2000 USD 2022-01-01 – 2022-12-31: 2000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Oruka Therapeutics, Inc. · 2022-12-31 Oruka Therapeutics, Inc. (edgar:907654) Capital Expenditure: 2000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T15:40:21Z Snapshot: bf025b1e1791244d1c34a3c2856ab5b9c5c3550eb14e95c1b413f80a21684075 Dimensions: Consolidated View: https://fundies.io/companies/edgar/907654/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea0205122-01.htm#6364143 Filing: 000121390024042529 The citation records this snapshot. The page link may show a newer release later.	−USD 10.91 million Calculation and evidence -10912000 − 2000 USD Exact free cash flow: -10914000 USD 2022-01-01 – 2022-12-31: -10912000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 2000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Oruka Therapeutics, Inc. · 2022-12-31 Oruka Therapeutics, Inc. (edgar:907654) Free cash flow: -10914000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T15:40:21Z Snapshot: bf025b1e1791244d1c34a3c2856ab5b9c5c3550eb14e95c1b413f80a21684075 Dimensions: Consolidated View: https://fundies.io/companies/edgar/907654?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -10912000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea0205122-01.htm#6352025 Filing: 000121390024042529 Input fundies:CapitalExpenditure: 2000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea0205122-01.htm#6364143 Filing: 000121390024042529 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 5.34 million Exact value Exact value: -5339000 USD 2023-01-01 – 2023-12-31: -5339000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Oruka Therapeutics, Inc. · 2023-12-31 Oruka Therapeutics, Inc. (edgar:907654) Net Income: -5339000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T15:40:21Z Snapshot: bf025b1e1791244d1c34a3c2856ab5b9c5c3550eb14e95c1b413f80a21684075 Dimensions: Consolidated View: https://fundies.io/companies/edgar/907654/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -5339000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea0205122-01.htm#6274930 Filing: 000121390024042529 The citation records this snapshot. The page link may show a newer release later.	−USD 5.01 million Exact value Exact value: -5014000 USD 2023-01-01 – 2023-12-31: -5014000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Oruka Therapeutics, Inc. · 2023-12-31 Oruka Therapeutics, Inc. (edgar:907654) Operating Cash Flow: -5014000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T15:40:21Z Snapshot: bf025b1e1791244d1c34a3c2856ab5b9c5c3550eb14e95c1b413f80a21684075 Dimensions: Consolidated View: https://fundies.io/companies/edgar/907654/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -5014000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea0205122-01.htm#6348894 Filing: 000121390024042529 The citation records this snapshot. The page link may show a newer release later.	USD 0 Exact value Exact value: 0 USD 2023-01-01 – 2023-12-31: 0 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Oruka Therapeutics, Inc. · 2023-12-31 Oruka Therapeutics, Inc. (edgar:907654) Capital Expenditure: 0 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T15:40:21Z Snapshot: bf025b1e1791244d1c34a3c2856ab5b9c5c3550eb14e95c1b413f80a21684075 Dimensions: Consolidated View: https://fundies.io/companies/edgar/907654/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 0 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/907654/000095017024009809/abio-20231231.htm#960185 Filing: 000095017024009809 The citation records this snapshot. The page link may show a newer release later.	−USD 5.01 million Calculation and evidence -5014000 − 0 USD Exact free cash flow: -5014000 USD 2023-01-01 – 2023-12-31: -5014000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 0 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Oruka Therapeutics, Inc. · 2023-12-31 Oruka Therapeutics, Inc. (edgar:907654) Free cash flow: -5014000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T15:40:21Z Snapshot: bf025b1e1791244d1c34a3c2856ab5b9c5c3550eb14e95c1b413f80a21684075 Dimensions: Consolidated View: https://fundies.io/companies/edgar/907654?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -5014000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea0205122-01.htm#6348894 Filing: 000121390024042529 Input fundies:CapitalExpenditure: 0 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/907654/000095017024009809/abio-20231231.htm#960185 Filing: 000095017024009809 The citation records this snapshot. The page link may show a newer release later.
2025 2025-01-01 – 2025-12-31	−USD 105.43 million Exact value Exact value: -105433000 USD 2025-01-01 – 2025-12-31: -105433000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Oruka Therapeutics, Inc. · 2025-12-31 Oruka Therapeutics, Inc. (edgar:907654) Net Income: -105433000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T15:40:21Z Snapshot: bf025b1e1791244d1c34a3c2856ab5b9c5c3550eb14e95c1b413f80a21684075 Dimensions: Consolidated View: https://fundies.io/companies/edgar/907654/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:NetIncome: -105433000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/907654/000121390026026929/ea0273300-10k_oruka.htm#1498449 Filing: 000121390026026929 The citation records this snapshot. The page link may show a newer release later.	−USD 88.21 million Exact value Exact value: -88210000 USD 2025-01-01 – 2025-12-31: -88210000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Oruka Therapeutics, Inc. · 2025-12-31 Oruka Therapeutics, Inc. (edgar:907654) Operating Cash Flow: -88210000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T15:40:21Z Snapshot: bf025b1e1791244d1c34a3c2856ab5b9c5c3550eb14e95c1b413f80a21684075 Dimensions: Consolidated View: https://fundies.io/companies/edgar/907654/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -88210000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/907654/000121390026026929/ea0273300-10k_oruka.htm#975907 Filing: 000121390026026929 The citation records this snapshot. The page link may show a newer release later.	USD 209,000 Exact value Exact value: 209000 USD 2025-01-01 – 2025-12-31: 209000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Oruka Therapeutics, Inc. · 2025-12-31 Oruka Therapeutics, Inc. (edgar:907654) Capital Expenditure: 209000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T15:40:21Z Snapshot: bf025b1e1791244d1c34a3c2856ab5b9c5c3550eb14e95c1b413f80a21684075 Dimensions: Consolidated View: https://fundies.io/companies/edgar/907654/explain?concept=fundies%3ACapitalExpenditure&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 209000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/907654/000121390026026929/ea0273300-10k_oruka.htm#977379 Filing: 000121390026026929 The citation records this snapshot. The page link may show a newer release later.	−USD 88.42 million Calculation and evidence -88210000 − 209000 USD Exact free cash flow: -88419000 USD 2025-01-01 – 2025-12-31: -88210000 USD · Inspect Operating Cash Flow · Source 2025-01-01 – 2025-12-31: 209000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Oruka Therapeutics, Inc. · 2025-12-31 Oruka Therapeutics, Inc. (edgar:907654) Free cash flow: -88419000 USD Concept: free-cash-flow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T15:40:21Z Snapshot: bf025b1e1791244d1c34a3c2856ab5b9c5c3550eb14e95c1b413f80a21684075 Dimensions: Consolidated View: https://fundies.io/companies/edgar/907654?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -88210000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/907654/000121390026026929/ea0273300-10k_oruka.htm#975907 Filing: 000121390026026929 Input fundies:CapitalExpenditure: 209000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/907654/000121390026026929/ea0273300-10k_oruka.htm#977379 Filing: 000121390026026929 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

193 filings · 3,371 latest values · 3,371 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0000907654, 907654, ABIO, ORKA, edgar:907654

Also known as ARCA BIOPHARMA, INC., ARCA Biopharma, Inc., ARCA biopharma, Inc., HYSEQ INC, NUVELO INC, Oruka Therapeutics, Inc.

Oruka Therapeutics, Inc.

Latest quarter

Revenue

Operating cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Capital expenditure

Free cash flow

Company performance

What changed year over year

Where revenue goes

2023 2023-01-01 – 2023-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation